Arrowhead Pharmaceuticals
arrowheadpharma.com · Healthcare · ARWR
Ranked 1,161 of 2,047 companies in the study
- Visibility5
- Citations0
- Sentiment75
- Site quality87
- AI readiness7
The AI assistants rarely name Arrowhead Pharmaceuticals: they mention the company in 2 of 60 answers, sometimes alongside Alnylam Pharmaceuticals. Its overall score is 31 out of 100, ranking 1,161st of 2,047 companies in the study. The website passes 1 of 14 technical checks for readiness with AI tools.
We asked 15 unbranded questions about the healthcare market: none named Arrowhead Pharmaceuticals. AI assistants named it in 2 of 60 answers (3.3%). The typical healthcare company is named in 3.3% of answers. By how often it is named, Arrowhead Pharmaceuticals ranks 48 of 105 in its sector.
Named fewer than three times in total. Read this as a sign that AI assistants rarely bring this company up, not as an exact comparison with its rivals.
Every dot is a company in the study. Hover one to see it; click to open its report.
This companySame sectorEvery other companyNever named
Five parts, each scored out of 100.
How often AI assistants name the company
How often AI uses the company's own website as a source
How positively AI describes the company
How well built the website's own pages are
How easily AI tools can read and use the website
Visibility is calculated from the answers on this page. How the score is built.
105 companies in this sector. The line on each bar is the typical company.
An answer that names the company
“Best RNAi-based options for treating conditions with limited existing therapies”
RNA interference (RNAi) therapies offer a promising approach for treating conditions with limited existing options by silencing genes that cause disease. This innovative class of medicines targets the root cause of diseases by preventing the production of specific, disease-associated proteins.
Here are some of the best RNAi-based options and areas of development:
Approved RNAi Therapies for Rare Genetic Disorders and Other Conditions:
Several RNAi therapies have already received regulatory approval, demonstrating the success of this technology:
Patisiran (Onpattro): The first FD …
The AI’s answer as we received it, shortened and not checked for accuracy.
How the mentions in these answers were split between this company and its rivals
Answers naming it, out of answers received
What this website publishes for an AI agent to read, use and buy from, on a scale of six levels.
- 0
- 1
- 2
- 3
- 4
- 5
Level 0: Not yet agent-ready. Agents struggle to find basic information about the site.
- 2 of robots.txt, Sitemap, Link headers
Show every check, for your technical teamHide the checks
- study: 92.0%robots.txtNot met
Publish a valid robots.txt with crawl rules and a Sitemap line.
- study: 86.8%SitemapNot met
Serve an XML sitemap and reference it from robots.txt.
- study: 0.3%Link headersNot met
Send Link headers such as rel="api-catalog" or rel="describedby" on the homepage.
- study: 5.5%DNS for AI DiscoveryNot present
Advertise agent endpoints with SVCB records under _agents.
- study: 1.9%Markdown negotiationNot met
Return a markdown version when asked with Accept: text/markdown, for example at the CDN.
- study: 25.1%llms.txtNot met
Publish an llms.txt with a short summary and the key links.
- study: 93.4%AI bot rulesPartly met
Add explicit robots.txt groups for the main AI crawlers.
- study: 1.4%Content SignalsNot met
Add a Content-Signal line for search, ai-input and ai-train to robots.txt.
- study: 0.2%Web Bot AuthNot present
Only relevant if you run your own agents or crawlers: publish a signing key directory.
- study: 0.3%API CatalogNot met
List public APIs in a linkset at /.well-known/api-catalog.
- study: 11.8%OAuth discoveryNot met
Publish OpenID Connect or OAuth server metadata under /.well-known.
- study: 10.3%OAuth Protected ResourceNot met
Serve protected resource metadata at /.well-known/oauth-protected-resource.
- study: 0.0%auth.mdNot met
Publish an auth.md describing how agents sign in.
- study: 0.2%MCP Server CardNot met
Offer an MCP server and publish its server card under /.well-known.
- study: 0.1%A2A Agent CardNot met
Publish an agent card at /.well-known/agent-card.json.
- study: 0.2%Agent SkillsNot met
Publish a skills index with the main tasks agents can do.
- study: 33.7%WebMCPCould not check
Register key actions such as search or cart as WebMCP tools.
- study: 0.1%ARD manifestNot met
Publish an ai-catalog.json listing every agent interface.
Score 7 of 100 · 97% of checks could run · checked on October 5, 2026 · arrowheadpharma.com · 2,047 companies scanned
1 of 14 passed. This list is for your technical team. The percentage is how many companies in the study pass each check.
These 14 checks ran during the audit and are what the AI readiness part of the overall score counts. The scan above ran later and is stricter on Link headers and Markdown, so a check can pass here and not there.
Show the 14 checksHide them
- Not metrobots.txt publishedstudy: 85.0%
- Not metXML sitemapstudy: 73.2%
- Not metHTTP Link headers (RFC 8288)study: 29.0%
- Not metMarkdown content negotiationstudy: 8.3%
- Not metllms.txt publishedstudy: 21.7%
- PassedToken budget (page weight)study: 95.2%
- Not metExplicit AI bot rulesstudy: 13.0%
- Not metAPI Catalog (.well-known/api-catalog)study: 0.2%
- Not metOAuth Authorization Server discoverystudy: 10.1%
- Not metOAuth Protected Resource discoverystudy: 9.3%
- Not metMCP Server Cardstudy: 0.0%
- Not metA2A Agent Cardstudy: 0.0%
- Not metWebMCP toolsstudy: 4.2%
- Not metAgent Skills declaredstudy: 0.0%
How many times each website was listed as a source in these answers
In the study as US-listed.
- How are pricing and reimbursement determined for advanced RNAi treatments in the US?
- Expected out-of-pocket costs for patients receiving RNA interference therapies
- What other modalities exist for targeting disease-causing genes besides RNAi?
- Why might an RNAi therapy stop being effective after initial success?
- What are the latest breakthroughs in RNA interference therapies for genetic diseases?
- RNAi therapeutics vs traditional small molecule drugs — key differences and benefits
- Are RNAi-based therapies worth considering for rare genetic disorders?
- Best RNAi-based options for treating conditions with limited existing therapies
- Emerging trends in clinical trials for RNA interference–based therapeutics
- Alternative approaches to gene silencing beyond RNA interference
- How are RNA interference technologies used for targeting hepatology indications?
- What are common side effects seen with RNA-interference–based therapeutics?
- Typical patient profiles that benefit most from gene-silencing RNA therapies
- Comparison of RNA interference and antisense oligonucleotide therapy mechanisms
- How effective are gene-targeted therapies using RNA interference for treating chronic diseases?
Columns, left to right: OpenAI, Claude, Perplexity, Gemini. The AI assistants often disagree. Across the study, on 40% of the questions where a company is named, only one of the four names it.